Endovascular therapy versus femoropopliteal bypass surgery for medium-length TASC II B and C lesions of the superficial femoral artery: An observational propensity-matched analysis

Abstract

Objectives

This study was designed to compare clinical outcomes of percutaneous transluminal angioplasty with optional stenting (PTA/s) and femoropopliteal bypass (FPB) surgery as primary invasive treatment in patients with medium-length superficial femoral artery (SFA) lesions.

Methods

We performed a single-center retrospective, observational analysis in all consecutive patients who had undergone initial invasive treatment for medium-length, TASC II B and TASC II C, SFA lesions from 2004 to 2015. Primary endpoints were primary and secondary clinical patency. Secondary endpoints were complication rates and number of amputations. Kaplan–Meier curves were used to compare patency rates in the two treatment groups. Multivariate Cox regression analysis was performed to adjust for confounding variables and propensity score matching analysis was used to balance treatment groups.

Results

A total of 362 patients with a mean observation period of 4.0 years (SD ± 2.6) were analyzed. In this group, 231 patients (64%) underwent PTA/s and 131 patients (36%) FPB surgery. There was no difference in primary clinical patency at one-, three- and five-year follow-up between the PTA/s and FPB group, with rates of 79% vs. 63%, 53% vs. 78% and 71% vs. 66%, respectively (P = 0.46). Secondary clinical patency estimates were comparable, resulting in one-, three- and five-year secondary clinical patency rates of 88%, 76% and 67% in the PTA/s group versus 88%, 80% and 79% in the bypass group (P = 0.40). Multivariate analysis revealed no significant differences between the PTA/s and FPB groups in terms of primary clinical patency (HR 1.4; 95% CI 0.9–2.2) and secondary clinical patency (HR 1.7; 95% CI 0.9–2.9). This was confirmed in the propensity score analysis. Hospital stay (4.8 vs. 10.3 days) and complication rate (2.6% vs. 18.3%) were significantly lower in the PTA/s group (P = 0.00). The number of amputations was comparable (P = 0.75).

Conclusions

The clinical success of endovascular therapy and surgery for medium-length SFA lesions is comparable. Taking into account the lower morbidity rate, shorter length of hospital stay and the less invasive character of PTA/s compared with bypass surgery, patients with medium-length SFA lesions are ideally treated by an endovascular-first approach.

Keywords

Angioplasty bypass surgery femoropopliteal propensity score endovascular stent

Get full access to this article

View all access options for this article.

References

National Institute for Health and Clinical Excellence. Lower limb peripheral arterial disease: diagnosis and management (Clinical guideline 147.), http://guidance.nice.org.uk/CG147 (2012, accessed 26 February 2019).

Vahl

Reekers

JA.

The guideline 'Diagnosis and treatment of peripheral artery disease of the lower extremities' of The Netherlands Surgical Society. Ned Tijdschr Geneeskd 2005; 149: 1670–1674.

Lindgren

Gottsäter

Qvarfordt

, et al. Invasive treatment for infrainguinal claudication has satisfactory 1 year outcome in three out of four patients: a population-based analysis from Swedvasc. Eur J Vasc Endovasc Surg 2014; 47: 615–620.

Norgren

Hiatt

Dormandy

, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33: S1–75.

Tsai

Rehring

Rogers

, et al. The contemporary safety and effectiveness of lower extremity bypass surgery and peripheral endovascular interventions in the treatment of symptomatic peripheral arterial disease. Circulation 2015; 132: 1999–2011.

Joels

York

Kalbaugh

, et al. Surgical implications of early failed endovascular intervention of the superficial femoral artery. J Vasc Surg 2008; 47: 562–565.

Darling

McCallum

Soden

, et al. Results for primary bypass versus primary angioplasty/stent for lower extremity chronic limb-threatening ischemia. J Vasc Surg 2017; 66: 466–475.

Aboyans

Ricco

Bartelink

MEL

, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS), European Journal of Vascular and Endovascular Surgery, http://doi.org/ (2017, accessed 26 February 2019). [10.1016/j.ejvs.2017.07.018]

Bradbury

Adam

Bell

, et al. Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial. Health Technol Assess 2010; 14: 1–210, iii–iv.

10.

Antoniou

Chalmers

Georgiadis

, et al. A meta-analysis of endovascular versus surgical reconstruction of femoropopliteal arterial disease. J Vasc Surg 2013; 57: 242–253.

11.

Vossen RJ, Vahl AC, Leijdekkers VJ, et al. Long-term clinical outcomes of percutaneous transluminal angioplasty with optional stenting in patients with superficial femoral artery disease: a retrospective, observational analysis. Eur J Vasc Endovasc Surg 2018; 56: 690--698.

12.

von Elm

Altman

Egger

, et al. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg 2014; 12: 1495–1499.

13.

von Allmen

Weiss

Tevaearai

, et al. Completeness of follow-up determines validity of study findings: results of a prospective repeated measures cohort study. PLoS One 2015; 10: e0140817.

14.

Rabellino

Zander

Baldi

, et al. Clinical Follow-up in endovascular treatment for TASC-C-D lesions in femoro-popliteal segment. Catheter Cardiovasc Interv 2009; 73: 701–705.

15.

Baril

Marone

Kim

, et al. Outcomes of endovascular interventions for TASC II B and C femoropopliteal lesions. J Vasc Surg 2008; 48: 627–633.

16.

Conrad

Cambria

Stone

, et al. Intermediate results of percutaneous endovascular therapy of femoropopliteal occlusive disease: a contemporary series. J Vasc Surg 2006; 44: 762–769.

17.

Van der Zaag

Legemate

Prins

, et al. Angioplasty or bypass for superficial femoral artery disease? A randomised controlled trial. Eur J Vasc Endovasc Surg 2004; 28: 132–137.

18.

Dosluoglu

Cherr

Lall

, et al. Stenting vs. above knee polytetrafluoroethylene bypass for TransAtlantic Inter-Society Consensus-II C and D superficial femoral artery disease. J Vasc Surg 2008; 48: 1166–1174.

19.

Surowiec

Davies

Eberly

, et al. Percutaneous angioplasty and stenting of the superficial femoral artery. J Vasc Surg 2005; 41: 269–278.

20.

Scali

REM

Bjerke

Stone

, et al. Long-term results of open and endovascular revascularization of superficial femoral artery occlusive disease. J Vasc Surg 2011; 54: 714–721.

21.

Kudo

Chandra

Kwun

, et al. Changing pattern of surgical revascularization for critical limb ischemia over 12 years: endovascular vs. open bypass surgery. J Vasc Surg 2006; 44: 304–313.

22.

Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355: 346–351.

23.

Geraghty

Welch

Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev 2011; 6: CD000536.

24.

Robertson

Ghouri

Kovacs

Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2012; 8: CD002071.

25.

Mahler

Low-dose aspirin combined with dipyridamole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty. Radiology 1994; 193: 567–571.

26.

Pilger

Lammer

Bertuch

, et al. Nd:YAG laser with sapphire tip combined with balloon angioplasty in peripheral arterial occlusions. Long-term results. Circulation 1991; 83: 141–147.

27.

WAVE Investigators. The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta‐analysis of trials. Am Heart J 2006; 151: 1–9.

28.

Mays

Casserly

Kohrt

, et al. Assessment of functional status and quality of life in claudication. J Vasc Surg 2011; 53: 1410–1421.

29.

Landry

GJ.

Functional outcome of critical limb ischemia. J Vasc Surg 2007; 45: A141–A148.

30.

Jens

Conijn

Koelemay

, et al. Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (Part 1: Above the knee). Eur J Vasc Endovasc Surg 2014; 47: 524–535.

31.

Jens

Conijn

Koelemay

, et al. Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (Part 2: Below the knee). Eur J Vasc Endovasc Surg 2014; 47: 536–544.